Re-evaluation of the cost effectiveness of the ACTH in the adjuvant treatment of breast cancer was timely given the emergence of TCH as a more effective option than the previous standard and significant changes in the relative costs of ACTH. This evidence concerns the gene POMC and breast cancer.